Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of$ 10.71.The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of$ 3.79 billion.Eylea PerformanceIn the quarter, U.S. net sales for Eylea HD and Eylea decreased 28% year-over-year to $1.08 billion, including$ 506 million from Eylea HD and $577 million from Eylea.In November 2025, the U.S. Food and Drug Administ ...